BMS Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

February 3, 2017
by Stephanie Chisolm

BCAN applauds the U.S. Food and Drug Administration (FDA) for approving Opdivo for use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

“Although bladder cancer is the 5th most commonly diagnosed cancer in the United States, it is only recently that we are starting to see new treatments being approved to help patients with this disease,” according to Andrea Maddox-Smith, CEO of BCAN.  “The FDA’s approval of Opdivo offers a much-needed treatment option for the bladder cancer community. We are grateful that the FDA moved swiftly to review and approve Opdivo and are very thankful to those patients and families who participated in the clinical trials for this drug.  We are hopeful that there will be more new therapies approved for all stages of bladder cancer in the near future.”

Read more about Opdivo here.

Read BCAN press release here.

Share this page:Share on FacebookTweet about this on TwitterShare on Google+Share on TumblrShare on LinkedInEmail this to someone